Clinical Trial Update: BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis [Phase 2]

View source ↗

Summary

Biogen's BG00012 (dimethyl fumarate) Phase 2 combination trial in multiple sclerosis has completed, with results posted in June 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• BG00012 (dimethyl fumarate)

Snippet

Sponsor: Biogen | Conditions: Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis | Phase 2 | Status: COMPLETED | Results posted: 2015-06-09